The FDA has now approved the use of teplizumab (Tzield), the world’s first ever immunotherapy for Type 1 diabetes, by people at risk of Type 1 diabetes.
A clinical trial found that teplizumab can delay Type 1 diabetes by an average of three years in people at high risk of developing the condition.
Chris Askew OBE, Chief Executive at Diabetes UK, said: “Today’s landmark approval of teplizumab in the US is the start of a seismic shift in how Type 1 diabetes is treated. For 100 years, people living with Type 1 diabetes have relied on insulin to treat the condition, and today’s decision means that for the first time, the root cause of the condition – an immune system attack – can be tackled, and Type 1 diabetes potentially delayed for up to three years.”
To read more, CLICK HERE.